CO6251370A2 - Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma - Google Patents
Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la mismaInfo
- Publication number
- CO6251370A2 CO6251370A2 CO10002346A CO10002346A CO6251370A2 CO 6251370 A2 CO6251370 A2 CO 6251370A2 CO 10002346 A CO10002346 A CO 10002346A CO 10002346 A CO10002346 A CO 10002346A CO 6251370 A2 CO6251370 A2 CO 6251370A2
- Authority
- CO
- Colombia
- Prior art keywords
- amino acid
- acid sequence
- variable domain
- chain variable
- humanized
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención proporciona materiales y métodos para el tratamiento de enfermedades que involucran actividad aberrante de células B, utilizando una molécula de unión específica CD20, en particular, anticuerpos o el fragmento de unión a antígeno de los mismos. Las composiciones descritas aquí son útiles para tratamiento y diagnóstico de Trastornos de célula B, tal como Malignidades de células B y enfermedades autoinmunes. 1.- Una molécula de unión CD20 humanizada que comprende un dominio variable da cadena pesada de inmunoglobulina (VH) y un dominio variable de cadena liviana de inmunoglobulina (VL) que comprende regiones de estructura y regiones CDR1, CDR2 y CDR3, en donde dichas regiones de estructura son regiones de estructura de inmunoglobulina humana y en donde: (a) la secuencia de aminoácido de dominio VH comprende la secuencia de aminoácido de un CDR3 de cadena pesada encontrado en una cualquiera de la SEQ ID NOS: 1-59; o (b) la secuencia de aminoácido de dominio VL comprende la secuencia de aminoácido de un CDR3 de cadena liviana encontrado en una cualquiera de la SEQ ID NOS: 1-59; o(c) la molécula de unión del CD20 humanizado comprende una secuencia de aminoácido VH de (a) y una secuencia de aminoácido VL de (b); o (d) la molécula de unión del CD20 humanizado comprende una secuencia de aminoácido VH de (a) y una secuencia de aminoácido VL de (b) y en donde dichos VH y VL se encuentran en la misma secuencia de referencia, o un fragmento de unión CD20 de dicha molécula de unión.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93434107P | 2007-06-12 | 2007-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6251370A2 true CO6251370A2 (es) | 2011-02-21 |
Family
ID=39884723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO10002346A CO6251370A2 (es) | 2007-06-12 | 2010-01-12 | Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100330089A1 (es) |
| EP (1) | EP2164871A2 (es) |
| JP (1) | JP2010531137A (es) |
| KR (1) | KR20100044160A (es) |
| CN (1) | CN101842389A (es) |
| AU (1) | AU2008266952A1 (es) |
| BR (1) | BRPI0812562A2 (es) |
| CA (1) | CA2691322A1 (es) |
| CO (1) | CO6251370A2 (es) |
| IL (1) | IL202684A0 (es) |
| MX (1) | MX2009013656A (es) |
| RU (1) | RU2010100638A (es) |
| WO (1) | WO2008156713A2 (es) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2691378A1 (en) | 2007-07-02 | 2009-01-08 | Oncomed Pharmaceuticals, Inc. | Antibody against human r-spondin (rspo) and use thereof for inhibition of beta-catenin signaling and treatment of cancer |
| TW201021831A (en) * | 2008-11-17 | 2010-06-16 | Genentech Inc | Method and formulation for reducing aggregation of a macromolecule under physiological conditions |
| EP2406274A2 (en) | 2009-03-11 | 2012-01-18 | Wyeth LLC | Methods of purifying small modular immunopharmaceutical proteins |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| CN106399276B (zh) | 2009-11-02 | 2021-08-10 | 华盛顿大学 | 治疗性核酸酶组合物和方法 |
| BR112012020102A2 (pt) * | 2010-02-10 | 2016-11-29 | Immunogen Inc | anticorpos cd20 e usos dos mesmos. |
| US9175086B2 (en) | 2010-02-10 | 2015-11-03 | Immunogen, Inc. | CD20 antibodies and uses thereof |
| AU2011283694B2 (en) | 2010-07-29 | 2017-04-13 | Xencor, Inc. | Antibodies with modified isoelectric points |
| EP2704737B1 (en) | 2011-04-29 | 2018-01-10 | University of Washington | Therapeutic nuclease compositions and methods |
| KR20140048276A (ko) | 2011-07-15 | 2014-04-23 | 온코메드 파마슈티칼스, 인크. | Rspo 결합제 및 이의 용도 |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| EP2780372B1 (en) * | 2011-11-17 | 2019-01-02 | Jung, Gundram | Bi-specific antibodies for medical use |
| CA2853138A1 (en) | 2011-12-05 | 2013-06-13 | Immunomedics, Inc. | Therapeutic use of anti-cd22 antibodies for inducing trogocytosis |
| US9757458B2 (en) | 2011-12-05 | 2017-09-12 | Immunomedics, Inc. | Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells |
| WO2013109904A1 (en) * | 2012-01-19 | 2013-07-25 | University Of Miami | Compositions, methods and kits for treatment of cancer and autoimmune diseases |
| MX2015000565A (es) | 2012-07-13 | 2015-04-10 | Oncomed Pharm Inc | Agentes de union de proteina de r-espondina humana (rspo3) y usos de los mismos. |
| US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
| US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| CA2897987A1 (en) | 2013-01-15 | 2014-07-24 | Xencor, Inc. | Rapid clearance of antigen complexes using novel antibodies |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
| US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| AU2014232416B2 (en) | 2013-03-15 | 2017-09-28 | Xencor, Inc. | Modulation of T Cells with Bispecific Antibodies and FC Fusions |
| PL3063275T3 (pl) | 2013-10-31 | 2020-03-31 | Resolve Therapeutics, Llc | Terapeutyczne fuzje nukleaza-albumina i sposoby |
| CA2933881A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
| BR112016022385A2 (pt) | 2014-03-28 | 2018-06-19 | Xencor, Inc | anticorpos específicos que se ligam a cd38 e cd3 |
| JP2017526356A (ja) * | 2014-08-15 | 2017-09-14 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｒｓｐｏ１結合剤およびその使用 |
| EP3193935A4 (en) | 2014-09-16 | 2018-03-21 | Oncomed Pharmaceuticals, Inc. | Treatment of fibrotic diseases |
| EP3221351A4 (en) * | 2014-11-19 | 2018-06-27 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for cancer treating conditions relating to over expressions of epha2 |
| EA037065B1 (ru) | 2014-11-26 | 2021-02-01 | Ксенкор, Инк. | Гетеродимерные антитела, связывающие cd3 и cd38 |
| US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
| TN2017000223A1 (en) | 2014-11-26 | 2018-10-19 | Xencor Inc | Heterodimeric antibodies that bind cd3 and tumor antigens |
| EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
| WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
| CA3007030A1 (en) | 2015-12-07 | 2017-06-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and psma |
| CA3026151A1 (en) | 2016-06-14 | 2017-12-21 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
| JP7021127B2 (ja) | 2016-06-28 | 2022-02-16 | ゼンコア インコーポレイテッド | ソマトスタチン受容体２に結合するヘテロ二量体抗体 |
| US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| SG10201913823VA (en) | 2016-10-07 | 2020-03-30 | Novartis Ag | Chimeric antigen receptors for the treatment of cancer |
| AU2017342560B2 (en) | 2016-10-14 | 2022-03-17 | Xencor, Inc. | IL15/IL15Ralpha heterodimeric Fc-fusion proteins |
| US20180193003A1 (en) | 2016-12-07 | 2018-07-12 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3054632A1 (en) | 2017-03-30 | 2018-10-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| WO2019006472A1 (en) | 2017-06-30 | 2019-01-03 | Xencor, Inc. | TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS |
| CN112272563A (zh) | 2017-11-08 | 2021-01-26 | Xencor股份有限公司 | 使用新颖抗pd-1序列的双特异性和单特异性抗体 |
| US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| US11319355B2 (en) | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
| CN112469477A (zh) | 2018-04-04 | 2021-03-09 | Xencor股份有限公司 | 与成纤维细胞活化蛋白结合的异源二聚体抗体 |
| WO2019204665A1 (en) | 2018-04-18 | 2019-10-24 | Xencor, Inc. | Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof |
| JP2021520829A (ja) | 2018-04-18 | 2021-08-26 | ゼンコア インコーポレイテッド | ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質 |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| JP2022503959A (ja) | 2018-10-03 | 2022-01-12 | ゼンコア インコーポレイテッド | Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質 |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| WO2020180726A1 (en) | 2019-03-01 | 2020-09-10 | Xencor, Inc. | Heterodimeric antibodies that bind enpp3 and cd3 |
| EP3870261B1 (en) | 2019-12-13 | 2024-01-31 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| AU2022232375A1 (en) | 2021-03-09 | 2023-09-21 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
| JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2256134T3 (en) * | 2003-11-13 | 2014-02-24 | Hanmi Science Co Ltd | IgG Fc fragment to a drug carrier and process for preparation thereof |
| CA2616386A1 (en) * | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals Inc. | Single dose use of cd20-specific binding molecules |
| DK2298815T3 (en) * | 2005-07-25 | 2015-06-15 | Emergent Product Dev Seattle | B-CELL REDUCTION USING CD37 SPECIFIC AND CD20 SPECIFIC BINDING MOLECULES |
| SG172698A1 (en) * | 2006-06-12 | 2011-07-28 | Trubion Pharmaceuticals Inc | Single-chain multivalent binding proteins with effector function |
-
2008
- 2008-06-12 AU AU2008266952A patent/AU2008266952A1/en not_active Abandoned
- 2008-06-12 CN CN200880100872A patent/CN101842389A/zh active Pending
- 2008-06-12 US US12/664,166 patent/US20100330089A1/en not_active Abandoned
- 2008-06-12 MX MX2009013656A patent/MX2009013656A/es not_active Application Discontinuation
- 2008-06-12 WO PCT/US2008/007464 patent/WO2008156713A2/en active Application Filing
- 2008-06-12 EP EP08768486A patent/EP2164871A2/en not_active Withdrawn
- 2008-06-12 BR BRPI0812562A patent/BRPI0812562A2/pt not_active IP Right Cessation
- 2008-06-12 RU RU2010100638/10A patent/RU2010100638A/ru not_active Application Discontinuation
- 2008-06-12 JP JP2010512214A patent/JP2010531137A/ja not_active Withdrawn
- 2008-06-12 CA CA2691322A patent/CA2691322A1/en not_active Abandoned
- 2008-06-12 KR KR1020107000237A patent/KR20100044160A/ko not_active Application Discontinuation
-
2009
- 2009-12-10 IL IL202684A patent/IL202684A0/en unknown
-
2010
- 2010-01-12 CO CO10002346A patent/CO6251370A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010531137A (ja) | 2010-09-24 |
| AU2008266952A1 (en) | 2008-12-24 |
| US20100330089A1 (en) | 2010-12-30 |
| KR20100044160A (ko) | 2010-04-29 |
| IL202684A0 (en) | 2011-08-01 |
| WO2008156713A2 (en) | 2008-12-24 |
| RU2010100638A (ru) | 2011-07-20 |
| EP2164871A2 (en) | 2010-03-24 |
| MX2009013656A (es) | 2010-03-30 |
| CA2691322A1 (en) | 2008-12-24 |
| CN101842389A (zh) | 2010-09-22 |
| WO2008156713A3 (en) | 2009-05-28 |
| BRPI0812562A2 (pt) | 2019-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6251370A2 (es) | Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma | |
| CY1122315T1 (el) | Συνθεσεις αντισωματων για τη θεραπεια ογκων | |
| ES2547463T3 (es) | Moléculas de unión a ILT3 y usos de las mismas | |
| PE20190120A1 (es) | Moleculas de union a bcma y metodos de uso de las mismas | |
| PH12018502623A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| ES2523194T3 (es) | Anticuerpo monoclonal humano específico para cada tumor | |
| PH12020551173A1 (en) | Anti-pd-l1 antibodies and uses thereof | |
| EA201490053A1 (ru) | Антитела, которые связываются с ox40, и их применение | |
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| PE20110797A1 (es) | Anticuerpos anti mn | |
| PE20121552A1 (es) | Anticuerpos monoclonales anti cea humanizados de afinidad madura | |
| RS53750B1 (en) | NOTCH1 RECEPTOR BINDING AGENTS AND APPLICATION PROCEDURES | |
| JP2013519375A5 (es) | ||
| NZ628528A (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| AR082163A1 (es) | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos | |
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| PE20142322A1 (es) | Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc | |
| RS54088B1 (en) | B-CELL REDUCTION BY USING CD37-SPECIFIC AND CD20-SPECIFIC BINDING MOLECULES | |
| NO20090877L (no) | Antistoffer rettet mot alfaVbeta6 og anvendelser derav | |
| AR079458A2 (es) | Anticuerpo monoclonal quimerico que se une a cd45 | |
| ES2572177T3 (es) | Anticuerpos neutralizantes anti-B7RP1 humanos | |
| PE20131209A1 (es) | Anticuerpos anti-fap | |
| EA201190132A1 (ru) | Гуманизированные антитела, связывающиеся с cd19, и их применение | |
| PE20120475A1 (es) | Anticuerpos especificos para dkk-1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |